Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 10;192(32):E913-E918.
doi: 10.1503/cmaj.191587.

Investigation and management of erythrocytosis

Siraj Mithoowani  1 , Marissa Laureano  1 , Mark A Crowther  1 , Christopher M Hillis  2
Affiliations
Review

Investigation and management of erythrocytosis

Siraj Mithoowani et al. CMAJ. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Christopher Hillis received grant funding from Novartis Oncology and personal fees from Novartis Oncology, Bristol Myers Squibb and Celgene outside the submitted work. Mark Crowther serves on the advisory boards of Servier Canada, Asahi Kasei Corporation and Precision BioLogic, and the data safety and monitoring board of Bayer. He has received speaking fees from Pfizer, CSL Behring and Diagnostica Stago. He has equity ownership in Alnylam Pharmaceuticals. He is also the Leo Pharma Chair in Thromboembolism Research at McMaster University. No other competing interests were declared.

Figures

Figure 1:
Figure 1:
Practical diagnostic approach to erythrocytosis. *Some clinicians order determination of the erythropoietin level and JAK2 V617F mutation testing concurrently in settings when there is a high probability of diagnosing polycythemia vera. †Bone marrow biopsy is required to meet the World Health Organization 2016 diagnostic criteria if the hemoglobin level is less than 185 g/L (hematocrit 0.55) in men or less than 165 g/L (hematocrit 0.50) in women.
Figure 2:
Figure 2:
Bone marrow biopsy specimen of a patient with polycythemia vera. (A) Hypercellularity for age and panmyelosis (expansion of all myeloid elements of the bone marrow) (hematoxylin–eosin, ×40 magnification). (B) Panmyelosis and pleomorphic megakaryocytes (hematoxylin–eosin, ×200 magnification). Images courtesy of Dr. Catherine Ross, Pathology and Molecular Medicine, Juravinski Hospital, Hamilton, Ontario.
See this image and copyright information in PMC

Comment in

References

    1. Busque L, Porwit A, Day R, et al. Laboratory investigation of myeloproliferative neoplasms (MPNs): recommendations of the Canadian MPN Group. Am J Clin Pathol 2016;146:408–22. - PubMed
    1. Ma X, Vanasse G, Cartmel B, et al. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol 2008;83:359–62. - PubMed
    1. Titmarsh GJ, Duncombe AS, McMullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol 2014; 89:581–7. - PubMed
    1. Chambellan A, Chailleux E, Similowski TANTADIR Observatory Group. Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy [published erratum in Chest 2006;129:831]. Chest 2005; 128:1201–8. - PubMed
    1. McMullin MFF, Mead AJ, Ali S, et al. British Society for Haematology Guideline. A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: a British Society for Haematology guideline. Br J Haematol 2019;184:161–75. - PMC - PubMed